<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04416984</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-501A-201</org_study_id>
    <nct_id>NCT04416984</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2)</brief_title>
  <acronym>ALPHA-2</acronym>
  <official_title>A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allogene Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allogene Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the ALPHA-2 study is to assess the safety, efficacy, and cell kinetics of
      ALLO-501A in adults with relapsed or refractory large B-cell lymphoma after a lymphodepletion
      regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-501A</measure>
    <time_frame>28 days</time_frame>
    <description>Dose limiting toxicity is defined as protocol-defined ALLO-501A-related adverse events with onset within 28 days following infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Proportion of patients experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-501A</measure>
    <time_frame>33 days</time_frame>
    <description>Dose-limiting toxicity is defined as protocol-defined ALLO-647-related adverse events with onset within 33 days following 1st infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall Response Rate</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Overall response rate assessed by independent radiology review</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Incidence and severity of adverse events with ALLO-501A and ALLO-647 in combination with fludarabine/cyclophosphamide</measure>
    <time_frame>up to 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Cellular kinetics of ALLO-501A in target tissues</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Levels of Anti-CD19 CAR T cells in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Pharmacokinetics of ALLO-647</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Serum concentration levels of ALLO-647</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Immunogenicity against ALLO-501A and ALLO-647</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Detection of antibodies in blood against ALLO-501A and ALLO-647</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Immune monitoring after lymphodepletion regimen</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Detection of the following circulating cells: T cell subset, B lymphocytes, and NK cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Overall response rate</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Overall response rate per investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Time to response</measure>
    <time_frame>up to 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Duration of Response</measure>
    <time_frame>up to 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Progression free survival</measure>
    <time_frame>up to 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Overall survival</measure>
    <time_frame>up to 13 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Relapsed/Refractory Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>ALLO-501A, ALLO-647</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ALLO-501A</intervention_name>
    <description>ALLO-501A is an allogeneic CAR T cell therapy targeting CD19</description>
    <arm_group_label>ALLO-501A, ALLO-647</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-647</intervention_name>
    <description>ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen</description>
    <arm_group_label>ALLO-501A, ALLO-647</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>ALLO-501A, ALLO-647</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>ALLO-501A, ALLO-647</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed relapsed/refractory large B-cell lymphoma with at least one
             measurable lesion

          -  At least 2 prior lines of chemotherapy including an anthracycline and an anti-CD20
             monoclonal antibody

          -  Prior CD19 therapy allowed with evidence of CD19 positive relapse following any prior
             CD19-directed therapy, including cell therapies

          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1

          -  Absence of donor (product)-specific anti-HLA antibodies

          -  Adequate hematological, renal, liver, pulmonary, and cardiac functions

        Exclusion Criteria:

          -  Current or history of central nervous system (CNS) lymphoma

          -  Clinically significant CNS dysfunction

          -  Current thyroid disorder (including hyperthyroidism) with the exception of
             hypothyroidism controlled on stable dose of hormone replacement therapy

          -  Prior treatment with any anti-CD52 monoclonal antibody

          -  Active acute or chronic graft versus host disease (GVHD)

          -  Patients unwilling to participate in an extended safety monitoring period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Allogene</last_name>
    <phone>415-604-5696</phone>
    <email>clinicaltrials@allogene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218-1234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Winter</last_name>
      <phone>303-577-6491</phone>
      <email>Kristine.Winter@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Soto</last_name>
      <phone>813-745-4608</phone>
      <email>Rachel.soto@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SCRI</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Gordon</last_name>
      <phone>303-621-6197</phone>
      <email>Rob.Gordon@sarahcannon.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

